Pfizer Inc. $PFE Stock Sold by First Fiduciary Investment Counsel Inc.

First Fiduciary Investment Counsel Inc. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 6.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 239,084 shares of the biopharmaceutical company’s stock after selling 17,273 shares during the quarter. First Fiduciary Investment Counsel Inc.’s holdings in Pfizer were worth $6,819,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. raised its stake in Pfizer by 15.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 5,482,863 shares of the biopharmaceutical company’s stock valued at $132,365,000 after purchasing an additional 745,213 shares during the last quarter. Handelsbanken Fonder AB boosted its stake in Pfizer by 10.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 2,462,431 shares of the biopharmaceutical company’s stock worth $59,295,000 after purchasing an additional 232,528 shares during the last quarter. Leuthold Group LLC acquired a new stake in Pfizer during the 2nd quarter worth $4,887,000. Park National Corp OH grew its holdings in shares of Pfizer by 332.1% during the second quarter. Park National Corp OH now owns 242,081 shares of the biopharmaceutical company’s stock worth $5,829,000 after buying an additional 186,053 shares in the last quarter. Finally, 111 Capital purchased a new stake in shares of Pfizer during the second quarter worth $3,706,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: ELREXFIO delivered a Phase 3 win. Pfizer said the MagnetisMM-32 trial met its primary endpoint, showing a statistically significant and clinically meaningful progression-free-survival benefit in relapsed or refractory multiple myeloma. The result could support broader use of the drug and strengthen Pfizer’s oncology pipeline. Pfizer’s ELREXFIO Outperforms Standard Regimens and Meets Primary Endpoint
• Positive Sentiment: The FDA expanded the approval of TALZENNA plus XTANDI for earlier-line treatment of metastatic prostate cancer in patients with HRR gene mutations. The broader indication may increase the products’ commercial opportunity and diversify revenue beyond COVID products. FDA expands Pfizer’s Talzenna plus Xtandi approval
• Positive Sentiment: Analyst sentiment remained supportive. Scotiabank and Jefferies issued Buy ratings, while previews suggested Pfizer could beat upcoming earnings expectations. Pfizer’s recent results also exceeded consensus estimates for both revenue and adjusted earnings. Pfizer gets a Buy from Scotiabank
• Neutral Sentiment: Investors are focused on the upcoming Q3 report. Strong sales from newer medicines and a relatively attractive valuation could help, but the earnings release will need to demonstrate that Pfizer can offset ongoing COVID-product declines and longer-term patent risks. Pfizer Stock Ahead of Q3 Earnings
• Negative Sentiment: ELREXFIO’s benefit came with safety concerns. Reports highlighted higher infection rates, while median progression-free survival had not yet been reached. These details may temper the market’s reaction to the otherwise positive trial results. Pfizer’s ELREXFIO meets Phase 3 endpoint
• Negative Sentiment: Valuation and business-transition risks remain. Pfizer’s COVID revenue is declining, major products face future patent expirations, and one valuation analysis placed fair value near the current trading range, limiting perceived upside.

Pfizer Price Performance

Shares of PFE stock opened at $29.46 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The company has a market capitalization of $167.90 billion, a PE ratio of 38.76, a price-to-earnings-growth ratio of 2.04 and a beta of 0.32. The firm’s 50-day moving average is $28.46 and its two-hundred day moving average is $26.74. Pfizer Inc. has a 12 month low of $23.62 and a 12 month high of $30.44.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the prior year, the company posted $0.78 EPS. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be issued a $0.43 dividend. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 5.8%. Pfizer’s dividend payout ratio is currently 226.32%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Bank of America reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. BMO Capital Markets dropped their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a research note on Tuesday, October 13th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Finally, Scotiabank raised their target price on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 6th. Five research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.72.

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.